News | April 25, 2024
New chemical method could cut waste from drug production
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
FDA has concluded that this inspection is 'closed'
Submission based on results from pivotal phase III trial showing all primary endpoints met
CHL is strengthening its play in the fast-growing beauty and personal care sector
Subscribe To Our Newsletter & Stay Updated
